Artialis will be attending the FlandersBio workshop on issues in clinical studies

Published on 04/07/2013

Barriers to qualify a biomarker in drug development: lessons from osteoarthritis. 

Biomarker-supported development of therapeutics and (companion) diagnostics adds challenges to the process of conducting clinical trials. In terms of legislation, trial set-up and sampling strategy companies are confronted with many questions, few answers and even less practical advice. Therefore FlandersBio and Eurasanté kindly invite you to participate actively in their workshop on this topic. 

Barriers to qualify a biomarker in drug development: lessons from osteoarthritis Yves Henrotin, Professor of Physical Therapy and Rehabilitation, Director of the Bone and Cartilage Research and President of Artialis and Synolyne / University of Liège.


Bio-accelerator I, Marc Van Montagu meeting room, Technologiepark 21, 9052 Zwijnaarde, Belgium

 © Artialis - All rights reserved
Terms & conditions - Privacy Policy